Sandro Mazzaferro

Prof. Dr. Sandro Mazzaferro

Sapienza University
orcid

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in Minerva Urology and Nephrology
Verified
Journal Article
Closed access
ACAntonio Carbone
Antonio Carbone
YSYazan Al Salhi
Yazan Al Salhi
ATAndrea Tasca
Andrea Tasca
GPGiovanni Palleschi
Giovanni Palleschi
AFAndrea Fuschi
Andrea Fuschi
Antonio Luigi PastoreAntonio Luigi Pastore
Antonio Luigi Pastore
Currently, abdominal obesity has reached an epidemic stage and obesity represents an important challenge for worldwide health authorities. Epidemiologic studies have demonstrated that the stone risk incidence increases with Body Mass Index, through multiple pathways. Metabolic syndrome and diabetes are associated with an increased renal stones disease incidence. The aim of this systematic review was to investigate the prevalence, morbidity, risk factors involved in the association between obesity and urolithiasis. The search involved finding relevant studies from MEDLINE, EMBASE, Ovid, the Cochrane Central Register of Controlled Trials, CINAHL, Google Scholar, and individual urological journals between January 2001 and May 2017. The inclusion criteria were for studies written in the English language, reporting on the association between obesity and urinary stones. The underlying pathophysiology of stone formation in obese patients is thought to be related to insulin resistance, dietary factors, and a lithogenic urinary profile. Uric acid stones and calcium oxalate stones are observed frequently in these patients. Insulin resistance is thought to alter the renal acid-base metabolism, resulting in a lower urine pH, and increasing the risk of uric acid stone disease. Obesity is also associated with excess nutritional intake of lithogenic substances and with an increase in urinary tract infection incidence. Recent studies highlighted that renal stone disease increases the risk of myocardial infarction, progression of chronic kidney disease, and diabetes. Contemporary, bariatric surgery has been shown to be associated with hyperoxaluria and oxalate nephropathy. Certainly, the many health risks of obesity, including nephrolithiasis, will add more burden on urologists and nephrologists. Obesity related nephrolithiasis seems to necessitate weight loss as primary treatment, but the recognition of the associated complications is necessary to prevent induction of new and equally severe medical problems. The optimal approach to obesity control that minimizes stone risk needs to be determined in order to manage obesity-induced renal stones disease.

1 April 2018 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
ACAdrian Constantin Covic
Adrian Constantin Covic
MVMarc Vervloet
Marc Vervloet
ZMZiad A Massy
Ziad A Massy
PTPablo Ureña Torres
Pablo Ureña Torres
DGDavid Goldsmith
David Goldsmith
Mario CozzolinoMario Cozzolino
Mario Cozzolino

1 May 2014 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
MVMarc Vervloet
Marc Vervloet
ZMZiad A Massy
Ziad A Massy
VBVincent M Brandenburg
Vincent M Brandenburg
SMSandro Mazzaferro
Sandro Mazzaferro
Mario CozzolinoMario Cozzolino
Mario Cozzolino
CECKD-MBD Working Group of ERA-EDTA
CKD-MBD Working Group of ERA-EDTA

1 August 2017 in Journal of Urology
Verified
Journal Article
Closed access
GGGiovanni Gambaro
Giovanni Gambaro
ECEmanuele Croppi
Emanuele Croppi
DBDavid Bushinsky
David Bushinsky
PJPhilippe Jaeger
Philippe Jaeger
ACAdamasco Cupisti
Adamasco Cupisti
PFPietro Manuel Ferraro
Pietro Manuel Ferraro
Urolithiasis can impair kidney function. This literature review focuses on the risk of kidney impairment in stone formers, the specific conditions associated with this risk and the impact of urological surgery. The PubMed® and Embase® databases were searched for publications on urolithiasis, its treatment, and the risk of chronic kidney disease, end stage renal disease and nephrectomy in stone formers. In general, renal stone formers have twice the risk of chronic kidney disease or end stage renal disease, and for female and overweight stone formers the risk is even higher. Patients with frequent urinary tract infections, struvite stones, urinary malformations and diversions, malabsorptive bowel conditions and some monogenic disorders are at high risk for chronic kidney disease/end stage renal disease. Shock wave lithotripsy or minimally invasive urological interventions for stones do not adversely affect renal function. Declines in renal function generally occur in patients with preexisting chronic kidney disease or a large stone burden requiring repeated and/or complex surgery. Although the effect size is modest, urolithiasis may cause chronic kidney disease and, thus, it is mandatory to assess patients with renal stones for the risk of chronic kidney disease/end stage renal disease. We suggest that all guidelines dealing with renal stone disease should include assessment of this risk.

6 March 2013 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
AIAndrea Icardi
Andrea Icardi
EPErnesto Paoletti
Ernesto Paoletti
LNLuca De Nicola
Luca De Nicola
SMSandro Mazzaferro
Sandro Mazzaferro
RRRoberto Russo
Roberto Russo
Mario CozzolinoMario Cozzolino
Mario Cozzolino
Resistance to erythropoiesis-stimulating agents (ESAs) has been observed in a considerable proportion of patients with chronic kidney disease (CKD) and it is reportedly associated with adverse outcomes, such as increased cardiovascular morbidity, faster progression to end-stage renal disease (ESRD) and all-cause mortality. The major causes of ESA resistance include chronic inflammation producing suppressive cytokines of early erythroid progenitor proliferation. In addition, pro-inflammatory cytokines stimulate hepcidin synthesis thus reducing iron availability for late erythropoiesis. Recent studies showing an association in deficiencies of the vitamin D axis with low haemoglobin (Hb) levels and ESA resistance suggest a new pathophysiological co-factor of renal anaemia. The administration of either native or active vitamin D has been associated with an improvement of anaemia and reduction in ESA requirements. Notably, these effects are not related to parathyroid hormone (PTH) values and seem to be independent on PTH suppression. Another possible explanation may be that calcitriol directly stimulates erythroid progenitors; however, this proliferative effect by extra-renal activation of 1α-hydroxylase enzyme is only a hypothesis. The majority of studies concerning vitamin D deficiency or supplementation, and degree of renal anaemia, point out the prevalent role of inflammation in the mechanism underlying these associations. Immune cells express the vitamin D receptor (VDR) which in turn is involved in the modulation of innate and adaptive immunity. VDR activation inhibits the expression of inflammatory cytokines in stromal and accessory cells and up-regulates the lymphocytic release of interleukin-10 (IL-10) exerting both anti-inflammatory activity and proliferative effects on erythroid progenitors. In CKD patients, vitamin D deficiency may stimulate immune cells within the bone marrow micro-environment to produce cytokines, inducing impaired erythropoiesis. Immune activation involves the reticuloendothelial system, increasing hepcidin synthesis and functional iron deficiency. Consequences of this inflammatory cascade are erythropoietin (EPO) resistance and anaemia. Given the key role of inflammation in the response to EPO, the therapeutic use of agents with anti-cytokines properties, such as vitamin D and paricalcitol, may provide benefit in the prevention/treatment of ESA hyporesponsiveness.

3 July 2017 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
Pablo MolinaPablo Molina
Pablo Molina
JCJuan J. Carrero
Juan J. Carrero
JBJordi Bover
Jordi Bover
PCPhilippe Chauveau
Philippe Chauveau
SMSandro Mazzaferro
Sandro Mazzaferro
F(for the European Renal Nutrition (ERN) and Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD) Working Groups of the European Renal Association–European Dialysis Transplant Association (ERA‐EDTA)
for the European Renal Nutrition (ERN) and Chronic Kidney Disease‐Mineral and Bone Disorder (CKD‐MBD) Working Groups of the European Renal Association–European Dialysis Transplant Association (ERA‐EDTA)
The spectrum of activity of vitamin D goes beyond calcium and bone homeostasis, and growing evidence suggests that vitamin D contributes to maintain musculoskeletal health in healthy subjects as well as in patients with chronic kidney disease (CKD), who display the combination of bone metabolism disorder, muscle wasting, and weakness. Here, we review how vitamin D represents a pathway in which bone and muscle may interact. In vitro studies have confirmed that the vitamin D receptor is present on muscle, describing the mechanisms whereby vitamin D directly affects skeletal muscle. These include genomic and non‐genomic (rapid) effects, regulating cellular differentiation and proliferation. Observational studies have shown that circulating 25‐hydroxyvitamin D levels correlate with the clinical symptoms and muscle morphological changes observed in CKD patients. Vitamin D deficiency has been linked to low bone formation rate and bone mineral density, with an increased risk of skeletal fractures. The impact of low vitamin D status on skeletal muscle may also affect muscle metabolic pathways, including its sensitivity to insulin. Although some interventional studies have shown that vitamin D may improve physical performance and protect against the development of histological and radiological signs of hyperparathyroidism, evidence is still insufficient to draw definitive conclusions.